E-PAUse: Encouraging Proper Antibiotic Use in Outpatient Setting

Sponsor
Hamad Medical Corporation (Industry)
Overall Status
Recruiting
CT.gov ID
NCT06135376
Collaborator
Primary Health Care Corporation, Qatar (Other)
600,000
1
2
29.9
20046.7

Study Details

Study Description

Brief Summary

Specific Aim 1: To determine the knowledge, attitude, and practice (KAP) of PHCC physicians regarding appropriate prescription of antibiotics in the outpatient setting.

Hypothesis 1a: PHCC physicians will have adequate theoretical knowledge regarding use of antibiotics for upper respiratory tract infections.

Hypothesis 1b: Despite adequate theoretical knowledge, fear of complications of untreated infection and patient demand and expectations will drive inappropriate antibiotic prescription for upper respiratory tract infections

Specific Aim 2: To test the effectiveness of a comprehensive multi-component intervention in a cluster randomized trial upon rate of antibiotics prescription for upper respiratory tract infections in individuals aged > 2 years presenting to primary care by PHCC physicians Hypothesis 2: Compared with a single intervention, a comprehensive multi-component intervention package will be associated with a significant reduction in inappropriate antibiotic prescription.

Investigators will conduct this study in the Primary Healthcare Center (PHCC) setting in Qatar. Investigators will identify four large PHCCs from the existing active centers. The study has 2 parts. Part 1 corresponds to specific aim 1 and comprises of a KAP survey which will be carried out in all four PHCCs and will include all physicians. Part 2 corresponds to specific aim 2 and is a cluster randomized clinical trial in which Investigators will randomize the four PHCCs into two groups.

First group (2 PHCCs) will receive training in appropriate documentation of infections and antibiotics prescription and will continue to provide usual care. Second group (2 PHCCs) will receive the comprehensive multi-component intervention, which consists of four elements:

  1. Option for deferred prescription fulfilment;

  2. Education of staff regarding appropriate uses of antibiotics,

  3. algorithm-driven decision support tool,

  4. Feedback on individual and group performance.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: comprehensive multi-component interventions
N/A

Detailed Description

As above.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
600000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
E-PAUse: Encouraging Proper Antibiotic Use in Outpatient Setting
Actual Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Apr 30, 2026
Anticipated Study Completion Date :
Apr 30, 2026

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Control groups with single intervention

The control groups will each receive a single intervention which will be selected at random.

Behavioral: comprehensive multi-component interventions
It is a combination of educational and behavioral interventions. 4 PHCCs will be randomized to 2 groups: 2 PHCCs will receive single intervention and 2 PHCCs will receive all 4 interventions.

Experimental: Experimental group with 4 interventions

2 Primary Health Care Centers (PHCCs) will receive the comprehensive multi-component intervention, which consists of four elements: Option for deferred prescription fulfilment. Education of staff regarding appropriate uses of antibiotics. algorithm-driven decision support tool. Feedback on individual and group performance. The training will be repeated at monthly intervals over the 6-month intervention period.

Behavioral: comprehensive multi-component interventions
It is a combination of educational and behavioral interventions. 4 PHCCs will be randomized to 2 groups: 2 PHCCs will receive single intervention and 2 PHCCs will receive all 4 interventions.

Outcome Measures

Primary Outcome Measures

  1. Total number of antibiotics courses prescribed for URTIs [36 months]

    For each recorded diagnosis of URTI, investigators will count the number of persons who received an antibiotic prescription. All prescriptions regardless of drug, dose, route of administration and duration will be counted. Only one prescription per 30-day period will be counted to exclude those with ongoing, evolving, or unresolved infection.

  2. Proportion of antibiotics prescription dispensed for an inappropriate use [36 months]

    For each antibiotic prescription written for a URTI diagnosis, investigators will determine the appropriateness of antibiotics based on our previously published criteria.

Secondary Outcome Measures

  1. Rates of hospitalization in 28 days after the PHCC visit [36 months]

    Number of hospitalizations within 28 days of the index visit

  2. Rates of ED visits in 28 days after the PHCC visit [36 months]

    Number of ED visits within 28 days of the index visit

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years to 120 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients >2 years old presenting to any of the selected PHCCs (rationale: signs and symptoms of bacterial infection in very young children are more non-specific and empiric antibiotics are often indicated due to serious consequences of unrecognized and untreated bacterial infections)

  • Presenting with acute (<1 week of symptoms) upper respiratory tract infection (URTI) like illness including

  • common cold/acute rhinitis/nasopharyngitis

  • laryngitis/laryngotracheitis

  • Acute bronchitis

  • acute otitis media

  • influenza (confirmed or influenza-like illness)

  • pharyngitis/tonsillitis

  • acute sinusitis

Exclusion Criteria:
  • Known immune compromised status, e.g., cystic fibrosis, cancer, organ transplant recipient.

  • On immune suppressive therapy for any duration (e.g., steroids, disease modifying antirheumatic agents; cancer chemotherapy, anti-rejection drugs, etc.) in one year prior to presentation

  • Known or diagnosed bacterial cause of infection.

  • Severe systemic illness requiring referral to the emergency department or hospitalization within 24 hours of presentation

  • Known or suspected chronic obstructive pulmonary disease. Asplenic patients (anatomic or functional)

Contacts and Locations

Locations

Site City State Country Postal Code
1 PHCC Doha Qatar

Sponsors and Collaborators

  • Hamad Medical Corporation
  • Primary Health Care Corporation, Qatar

Investigators

  • Principal Investigator: Adeel A. Butt, MBBS, MS, Hamad Medical Corporation

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Adeel Ajwad Butt, Senior Consultant in Infectious Disease, Hamad Medical Corporation
ClinicalTrials.gov Identifier:
NCT06135376
Other Study ID Numbers:
  • MRC-01-23-076
First Posted:
Nov 18, 2023
Last Update Posted:
Nov 18, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Adeel Ajwad Butt, Senior Consultant in Infectious Disease, Hamad Medical Corporation

Study Results

No Results Posted as of Nov 18, 2023